Free Trial
NASDAQ:TELO

Telomir Pharmaceuticals 2/4/2025 Earnings Report

Telomir Pharmaceuticals logo
$2.62 +0.03 (+0.97%)
As of 10:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Telomir Pharmaceuticals EPS Results

Actual EPS
-$0.10
Consensus EPS
-$0.05
Beat/Miss
Missed by -$0.05
One Year Ago EPS
N/A

Telomir Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Telomir Pharmaceuticals Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Telomir Pharmaceuticals' next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

Telomir Pharmaceuticals Earnings Headlines

Telomir Pharmaceuticals, Inc. (TELO)
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More Telomir Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Telomir Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telomir Pharmaceuticals and other key companies, straight to your email.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals (NASDAQ:TELO), a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

View Telomir Pharmaceuticals Profile

More Earnings Resources from MarketBeat